Works matching IS 10452257 AND DT 2019 AND VI 58 AND IP 10

Results: 7

Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
Published in:
Genes, Chromosomes & Cancer, 2019, v. 58, n. 10, p. 698, doi. 10.1002/gcc.22761
By:
- Hartmann, Luise;
- Haferlach, Claudia;
- Meggendorfer, Manja;
- Kern, Wolfgang;
- Haferlach, Torsten;
- Stengel, Anna
Publication type:
Article
Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.
Published in:
Genes, Chromosomes & Cancer, 2019, v. 58, n. 10, p. 689, doi. 10.1002/gcc.22760
By:
- Ganster, Christina;
- Müller‐Thomas, Catharina;
- Haferlach, Claudia;
- Strupp, Corinna;
- Ogata, Kiyoyuki;
- Germing, Ulrich;
- Hildebrandt, Barbara;
- Mallo, Mar;
- Lübbert, Michael;
- Müller, Christel;
- Solé, Francesc;
- Götze, Katharina S.;
- Vandenberghe, Peter;
- Göhring, Gudrun;
- Steinmetz, Tilman;
- Kröger, Nicolaus;
- Platzbecker, Uwe;
- Söling, Ulrike;
- Raynaud, Sophie;
- Shirneshan, Katayoon
Publication type:
Article
Detecting disease‐defining gene fusions in unclassified round cell sarcomas using anchored multiplex PCR/targeted RNA next‐generation sequencing—Molecular and clinicopathological characterization of 16 cases.
Published in:
Genes, Chromosomes & Cancer, 2019, v. 58, n. 10, p. 713, doi. 10.1002/gcc.22763
By:
- Mantilla, Jose G.;
- Ricciotti, Robert W.;
- Chen, Eleanor;
- Hoch, Benjamin L.;
- Liu, Yajuan J.
Publication type:
Article
PRRX‐NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm.
Published in:
Genes, Chromosomes & Cancer, 2019, v. 58, n. 10, p. 705, doi. 10.1002/gcc.22762
By:
- Lacambra, Maribel D.;
- Weinreb, Ilan;
- Demicco, Elizabeth G.;
- Chow, Chit;
- Sung, Yun‐Shao;
- Swanson, David;
- To, Ka‐Fai;
- Wong, Kwok‐Chuen;
- Antonescu, Cristina R.;
- Dickson, Brendan C.
Publication type:
Article
Table of Content Volume 58, Number 10, October 2019.
Published in:
Genes, Chromosomes & Cancer, 2019, v. 58, n. 10, p. 687, doi. 10.1002/gcc.22660
Publication type:
Article
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.
Published in:
Genes, Chromosomes & Cancer, 2019, v. 58, n. 10, p. 723, doi. 10.1002/gcc.22765
By:
- de Smith, Adam J.;
- Lavoie, Geneviève;
- Walsh, Kyle M.;
- Aujla, Sumeet;
- Evans, Erica;
- Hansen, Helen M.;
- Smirnov, Ivan;
- Kang, Alice Y.;
- Zenker, Martin;
- Ceremsak, John J.;
- Stieglitz, Elliot;
- Muskens, Ivo S.;
- Roberts, William;
- McKean‐Cowdin, Roberta;
- Metayer, Catherine;
- Roux, Philippe P.;
- Wiemels, Joseph L.
Publication type:
Article
Genetic profiling of a chondroblastoma‐like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1‐FGFR1 gene fusion.
Published in:
Genes, Chromosomes & Cancer, 2019, v. 58, n. 10, p. 731, doi. 10.1002/gcc.22764
By:
- Saba, Karim H.;
- Cornmark, Louise;
- Rissler, Marianne;
- Fioretos, Thoas;
- Åström, Kristina;
- Haglund, Felix;
- Rosenberg, Andrew E.;
- Brosjö, Otte;
- Nord, Karolin H.
Publication type:
Article

Works matching IS 10452257 AND DT 2019 AND VI 58 AND IP 10

Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.

Detecting disease‐defining gene fusions in unclassified round cell sarcomas using anchored multiplex PCR/targeted RNA next‐generation sequencing—Molecular and clinicopathological characterization of 16 cases.

PRRX‐NCOA1/2 rearrangement characterizes a distinctive fibroblastic neoplasm.

Table of Content Volume 58, Number 10, October 2019.

Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children.

Genetic profiling of a chondroblastoma‐like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1‐FGFR1 gene fusion.